227 related articles for article (PubMed ID: 26139989)
1. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.
Mosińska P; Fichna J; Storr M
World J Gastroenterol; 2015 Jun; 21(24):7436-42. PubMed ID: 26139989
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.
Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H
Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606
[TBL] [Abstract][Full Text] [Related]
3. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K
BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162
[TBL] [Abstract][Full Text] [Related]
4. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs.
Taniguchi S; Yano T; Imaizumi M; Manabe N
Neurogastroenterol Motil; 2018 Dec; 30(12):e13448. PubMed ID: 30129138
[TBL] [Abstract][Full Text] [Related]
5. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A; Seki M; Taniguchi S
J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
[TBL] [Abstract][Full Text] [Related]
6. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M
Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674
[TBL] [Abstract][Full Text] [Related]
7. Elobixibat for the treatment of constipation.
Chedid V; Vijayvargiya P; Camilleri M
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
9. Elobixibat for the treatment of constipation.
Wong BS; Camilleri M
Expert Opin Investig Drugs; 2013 Feb; 22(2):277-84. PubMed ID: 23215781
[TBL] [Abstract][Full Text] [Related]
10. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.
Wong BS; Camilleri M; McKinzie S; Burton D; Graffner H; Zinsmeister AR
Am J Gastroenterol; 2011 Dec; 106(12):2154-64. PubMed ID: 21876564
[TBL] [Abstract][Full Text] [Related]
11. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.
Miner PB
Expert Opin Pharmacother; 2018 Aug; 19(12):1381-1388. PubMed ID: 30129377
[TBL] [Abstract][Full Text] [Related]
12. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
[TBL] [Abstract][Full Text] [Related]
13. Review article: Elobixibat: a novel treatment for chronic constipation.
Khanna L; Camilleri M
Aliment Pharmacol Ther; 2021 Jan; 53(2):234-242. PubMed ID: 33296518
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes.
Chen L; Yao X; Young A; McNulty J; Anderson D; Liu Y; Nystrom C; Croom D; Ross S; Collins J; Rajpal D; Hamlet K; Smith C; Gedulin B
Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E68-76. PubMed ID: 21934041
[TBL] [Abstract][Full Text] [Related]
15. Apple juice relieves loperamide-induced constipation in rats by downregulating the intestinal apical sodium-dependent bile acid transporter ASBT.
Zhu Q; Iwai R; Okaguchi T; Shirasaka Y; Tamai I
Food Funct; 2023 May; 14(10):4836-4846. PubMed ID: 37129213
[TBL] [Abstract][Full Text] [Related]
16. [Hypolipidemic drugs--ileal Na+/bile acid cotransporter inhibitors (S-8921 etc)].
Ichihashi T
Nihon Rinsho; 2002 Jan; 60(1):130-6. PubMed ID: 11808323
[TBL] [Abstract][Full Text] [Related]
17. ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery.
Yang N; Dong YQ; Jia GX; Fan SM; Li SZ; Yang SS; Li YB
Biomed Pharmacother; 2020 Dec; 132():110835. PubMed ID: 33035828
[TBL] [Abstract][Full Text] [Related]
18. Plecanatide (Trulance) for chronic idiopathic constipation.
Med Lett Drugs Ther; 2017 Apr; 59(1519):66-68. PubMed ID: 28419073
[No Abstract] [Full Text] [Related]
19. Ileal apical sodium-dependent bile acid transporter protein levels are down-regulated through ubiquitin-dependent protein degradation induced by bile acids.
Miyata M; Yamakawa H; Hayashi K; Kuribayashi H; Yamazoe Y; Yoshinari K
Eur J Pharmacol; 2013 Aug; 714(1-3):507-14. PubMed ID: 23872411
[TBL] [Abstract][Full Text] [Related]
20. New treatment options for chronic constipation: mechanisms, efficacy and safety.
Camilleri M
Can J Gastroenterol; 2011 Oct; 25 Suppl B(Suppl B):29B-35B. PubMed ID: 22114755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
